ArticleSisli Etfal Hastanesi tip bulteni2026
Antimicrobial Resistance Profile and Longitudinal Trends of
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Methods: This retrospective study analyzed Results: A total of 673 non-duplicate isolates were included, predominantly from urine (68.6%), followed by wound (19.2%), blood (4.7%), respiratory (3.6%), abscess (1.9%), and sterile body fluid (1.0%) specimens. The annual incidence ranged from 0.47% in 2015 to 1.9% in 2024, with a transient decline during 2020-2022, likely related to the COVID-19 pandemic. Male patients accounted for 63% of isolates, with a median age of 52 years. Meropenem and amikacin showed the highest overall activity (>98% susceptibility), while cefoxitin demonstrated the lowest efficacy (≈50%). Trend analysis revealed statistically significant increases in resistance to amikacin, imipenem, meropenem, ertapenem, ceftriaxone, ceftazidime, cefoxitin, cefepime, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and ciprofloxacin (all p<0.05), whereas gentamicin showed no significant change. Notably, carbapenem and aminoglycoside resistance increased markedly after 2022. Conclusion: This study highlights the rising clinical importance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.